Clinical characteristics of coronavirus disease 2019 (COVID-19) patients in Kuwait

Abdullah Alshukry 1, Hamad Ali 2 3, Yaseen Ali 1, Talal Al-Taweel 4, Mohammad Abu-Farha 3, Jehad AbuBaker 3, Sriraman Devarajan 3, Ali A Dashti 2, Ali Bandar 5, Hessah Taleb 6, Abdullah Al Bader 1, Nasser Y Aly 7, Ebaa Al-Ozairi 3, Fahd Al-Mulla 3, Mohammad Bu Abbas 1

Affiliations

20 November 2020

-

doi: 10.1371/journal.pone.0242768

Abstract

This is a retrospective single-center study of 417 consecutive patients with coronavirus disease 2019 (COVID-19) admitted to Jaber Al-Ahmad Hospital in Kuwait between February 24, 2020 and May 24, 2020. In total, 39.3% of patients were asymptomatic, 41% were symptomatic with mild/moderate symptoms, 19.7% were admitted to the intensive care unit (ICU). Most common symptoms in cohort patients were fever (34.3%) and dry cough (32.6%) while shortness in breath was reported in (75.6%) of ICU admissions. Reported complications requiring ICU admission included Sepsis (68.3%), acute respiratory distress syndrome (95.1%) and heart failure (63.4%). ICU patients were more likely to have comorbidities, in comparison to non-ICU patients, including diabetes (35.4% vs 20.3%) and hypertension (40.2% vs 26.9%). Mortality rate of cohort was 14.4% and mean age of death was 54.20 years (± 11.09) and 90% of death cases were males. Chest high-resolution computed tomography for ICU cases reveled multifocal large patchy areas of ground glass opacification mixed with dense consolidation. Cases admitted to ICU showed abnormal levels of markers associated with infection, inflammation, abnormal blood clotting, heart problems and kidney problems. Mean hospital stay for asymptomatic cases was 20.69 days ±8.57 and for mild/moderate cases was 21.4 days ±8.28. Mean stay in ICU to outcome for survivors was 11.95 days ±8.96 and for death cases 13.15 days ±10.02. In this single-center case series of 417 hospitalized COVID-19 patients in Kuwait 39.3% were asymptomatic cases, 41% showed mild/moderate symptoms and 18.7% were admitted to ICU with a mortality rate of 14.4%.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Hospitalization dynamics.

Fig 1. Hospitalization dynamics.

Fig 2. Categorical age structures. Each age group percentage is calculated by dividing the count by the total in each category. Highest ICU admissions were in the age groups (41–50 years) and (51–60 years) while highest numbers of death cases were recorded in the age group (51–60 years).

Fig 2. Categorical age structures. Each age group percentage is calculated by dividing the count by the total in each category. Highest ICU admissions were in the age groups (41–50 years) and (51–60 years) while highest numbers of death cases were recorded in the age group (51–60 years).

Fig 3. COVID-19 patients chest imaging. A. Normal chest radiography of a patient with mild to moderate COVID-19. B. Diffuse bilateral airspace opacification with patches of consolidation in an ICU survivor. C. Diffuse bilateral airspace opacification with consolidation patches in an ICU death. D. Diffuse bilateral airspace opacification with near total white out of both lung fields in an ICU death. E and F. High Resolution CT chest showing multifocal large patchy areas of ground glass opacification mixed with dense consolidations in an ICU death. show full caption

Fig 3. COVID-19 patients chest imaging. A. Normal chest radiography of a patient with mild to moderate COVID-19. B. Diffuse bilateral airspace opacification with patches of consolidation in an ICU survivor. C. Diffuse bilateral airspace opacification with consolidation patches in an ICU death. D. Diffuse bilateral airspace opacification with near total white out of both lung fields in an ICU death. E and F. High Resolution CT chest showing multifocal large patchy areas of ground glass opacification mixed with dense consolidations in an ICU death. show full caption

Fig 4. Dynamic Profile of certain laboratory markers in COVID-19 ICU patients. Laboratory tests were done on daily basis after disease onset. Dotted black lines indicate upper normal limit in A and B, and lower normal limit in C and F. (WBC: White blood cells, CRP: C-Reactive protein, PCT: Procalcitonin, eGFR: Estimated glomerular filtration rate).

Fig 4. Dynamic Profile of certain laboratory markers in COVID-19 ICU patients. Laboratory tests were done on daily basis after disease onset. Dotted black lines indicate upper normal limit in A and B, and lower normal limit in C and F. (WBC: White blood cells, CRP: C-Reactive protein, PCT: Procalcitonin, eGFR: Estimated glomerular filtration rate).

Similar articles

Real Asymptomatic SARS-CoV-2 Infection Might Be Rare: Importance of Careful Interviews and Follow-up.

Jeong TH, Pak C, Ock M, Lee SH, Son JS, Jeon YJ.J Korean Med Sci. 2020 Sep 21;35(37):e333. doi: 10.3346/jkms.2020.35.e333.PMID: 32959547 Free PMC article.

Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.

Khan M, Khan H, Khan S, Nawaz M.J Med Microbiol. 2020 Aug;69(8):1114-1123. doi: 10.1099/jmm.0.001231.PMID: 32783802 Free PMC article.

Intensive Care Unit Admissions During the First 3 Months of the COVID-19 Pandemic in Poland: A Single-Center, Cross-Sectional Study.

Kokoszka-Bargieł I, Cyprys P, Rutkowska K, Madowicz J, Knapik P.Med Sci Monit. 2020 Sep 26;26:e926974. doi: 10.12659/MSM.926974.PMID: 32979262 Free PMC article.

Intensive Care Unit Management of the Adult with Congenital Heart Disease.

Kendsersky P, Krasuski RA.Curr Cardiol Rep. 2020 Sep 10;22(11):136. doi: 10.1007/s11886-020-01389-9.PMID: 32910318 Free PMC article. Review.

How is the iceberg of COVID-19? Results from a rapid literature review.

Moradi G, Gholami F, Rasouli MA, Bagheri Amiri F, Moradi Y.Med J Islam Repub Iran. 2021 Jun 16;35:77. doi: 10.47176/mjiri.35.77. eCollection 2021.PMID: 34291001 Free PMC article. Review.

Cited by

Mortality, Intensive Care Unit Admission, and Intubation among Hospitalized Patients with COVID-19: A One-Year Retrospective Study in Jordan.

Al Oweidat K, Al-Amer R, Saleh MY, Albtoosh AS, Toubasi AA, Ribie MK, Hasuneh MM, Alfaqheri DL, Alshurafa AH, Ribie M, Ali AM, Obeidat N.J Clin Med. 2023 Apr 2;12(7):2651. doi: 10.3390/jcm12072651.PMID: 37048734 Free PMC article.

Understanding the Demographic, Clinical, and Real-Time Polymerase Chain Reaction Profiles of COVID-19 Patients in a Tertiary Care Hospital in Northeast India.

Dutta BS, Nath K, Taw MJ, Sharma A, Rajbongshi G, Chamuah K, Henbi N, Barman RK, Chingtham S, Brahma D, Sarmah K, Baruah P, Nath K, Choudhury PD, Mazumder D, Sarmah A, Sharma A, Hazarika B, Choudhury MK, Baishya AC.Cureus. 2023 Feb 24;15(2):e35426. doi: 10.7759/cureus.35426. eCollection 2023 Feb.PMID: 36860823 Free PMC article.

Clinical and Epidemiology Characteristics of COVID-19 Cases Detected During Mass Screening Campaign from July to October 2020 in Bujumbura, Burundi.

Nkunzimana E, Bizimana JC, Ndoreraho A, Iteka L, Butoyi P, Leopold O, Nyandwi J.East Afr Health Res J. 2022;6(2):127-133. doi: 10.24248/eahrj.v6i2.689. Epub 2022 Nov 30.PMID: 36751687 Free PMC article.

Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis.

Wang B, Andraweera P, Elliott S, Mohammed H, Lassi Z, Twigger A, Borgas C, Gunasekera S, Ladhani S, Marshall HS.Pediatr Infect Dis J. 2023 Mar 1;42(3):232-239. doi: 10.1097/INF.0000000000003791. Epub 2022 Dec 1.PMID: 36730054 Free PMC article.

Comorbid Asthma Increased the Risk for COVID-19 Mortality in Asia: A Meta-Analysis.

Shi L, Ren J, Wang Y, Feng H, Liu F, Yang H.Vaccines (Basel). 2022 Dec 30;11(1):89. doi: 10.3390/vaccines11010089.PMID: 36679934 Free PMC article. Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
  2.  
    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020. 10.1016/S1473-3099(20)30120-1 - DOI - PMC - PubMed
  3.  
    1. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020. 10.1001/jama.2020.2565 - DOI - PMC - PubMed
  4.  
    1. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020. 10.1016/j.jmii.2020.02.012 - DOI - PMC - PubMed
  5.  
    1. Eaaswarkhanth M, Al Madhoun A, Al-Mulla F. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality? Int J Infect Dis. 2020;96:459–60. 10.1016/j.ijid.2020.05.071 - DOI - PMC - PubMed
  6.  
    1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–9. 10.1038/s41586-020-2008-3 - DOI - PMC - PubMed
  7.  
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. 10.1001/jama.2020.1585 - DOI - PMC - PubMed
  8.  
    1. Ali H, Alshukry A, Bu Abbas M, Ali Y, Alahmad B, Al-Shammari AA, et al. Clinical Characteristics and Outcomes of Diabetic COVID-19 patients in Kuwait. medRxiv. 2020:2020.08.20.20178525. 10.1101/2020.08.20.20178525 - DOI
  9.  
    1. Alahmad B, Al-Shammari AA, Bennakhi A, Al-Mulla F, Ali H. Fasting Blood Glucose and COVID-19 Severity: Nonlinearity Matters. Diabetes Care. 2020. 10.2337/dc20-1941 . - DOI - PMC - PubMed
  10.  
    1. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663–5. 10.1056/NEJMc2005073 - DOI - PMC - PubMed
  11.  
    1. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020. 10.1126/science.abc3517 - DOI - PMC - PubMed
  12.  
    1. Al-Shammari AAA, Ali H, Al-Ahmad B, Al-Refaei FH, Al-Sabah S, Jamal MH, et al. Real-time tracking and forecasting of the COVID-19 outbreak in Kuwait: a mathematical modeling study. medRxiv. 2020:2020.05.03.20089771. 10.1101/2020.05.03.20089771 - DOI
  13.  
    1. Al-Hasan A, Yim D, Khuntia J. Citizens' Adherence to COVID-19 Mitigation Recommendations by the Government: A 3-Country Comparative Evaluation Using Web-Based Cross-Sectional Survey Data. J Med Internet Res. 2020;22(8):e20634 10.2196/20634 - DOI - PMC - PubMed
  14.  
    1. LoPresti M, Beck DB, Duggal P, Cummings DAT, Solomon BD. The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature. Am J Hum Genet. 2020;107(3):381–402. 10.1016/j.ajhg.2020.08.007 - DOI - PMC - PubMed
  15.  
    1. Al-Mulla F, Mohammad A, Al Madhoun A, Haddad D, Ali H, Eaaswarkhanth M, et al. A comprehensive germline variant and expression analyses of ACE2, TMPRSS2 and SARS-CoV-2 activator FURIN genes from the Middle East: Combating SARS-CoV-2 with precision medicine. bioRxiv. 2020:2020.05.16.099176. 10.1101/2020.05.16.099176 - DOI
  16.  
    1. Benetti E, Tita R, Spiga O, Ciolfi A, Birolo G, Bruselles A, et al. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. medRxiv. 2020:2020.04.03.20047977. 10.1038/s41431-020-0691-z - DOI - PMC - PubMed
  17.  
    1. Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, et al. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med Virol. 2020. 10.1002/jmv.25832 - DOI - PMC - PubMed
  18.  
    1. Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425–35. 10.1016/j.jmii.2020.04.015 - DOI - PMC - PubMed
  19.  
    1. Alahmad B, Kurdi H, Colonna K, Gasana J, Agnew J, Fox MA. COVID-19 stressors on migrant workers in Kuwait: cumulative risk considerations. BMJ Glob Health. 2020;5(7). 10.1136/bmjgh-2020-002995 . - DOI - PMC - PubMed
  20.  
    1. Al-Hasan A, Khuntia J, Yim D. Threat, coping and social distance adherence for COVID-19: Cross-continental comparison using online cross-sectional survey data. J Med Internet Res. 2020. 10.2196/23019 . - DOI - PMC - PubMed
  21.  
    1. Organization WH. Clinical management of COVID-19 Interim guidance. World Health Organization; 2020.
  22.  
    1. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33. 10.1001/jama.2012.5669 . - DOI - PubMed
  23.  
    1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100. 10.1111/j.1523-1755.2005.00365.x . - DOI - PubMed
  24.  
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. 10.1056/NEJMoa2002032 - DOI - PMC - PubMed
  25.  
    1. Bureau KCS. Population estimates in Kuwait by Age, Nationality and sex at 1L1L2019. 2019. Contract No.: 10/6/2020.
  26.  
    1. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv. 2020:2020.05.10.20097543. 10.1101/2020.05.10.20097543 - DOI
  27.  
    1. Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. JAMA Netw Open. 2020;3(5):e2010182 10.1001/jamanetworkopen.2020.10182 - DOI - PMC - PubMed
  28.  
    1. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020;382(22):2158–60. 10.1056/NEJMe2009758 - DOI - PMC - PubMed
  29.  
    1. Spychalski P, Blazynska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020. 10.1016/S1473-3099(20)30246-2 - DOI - PMC - PubMed
  30.  
    1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020. 10.1001/jama.2020.6775 - DOI - PMC - PubMed
  31.  
    1. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020;8:152 10.3389/fpubh.2020.00152 - DOI - PMC - PubMed
  32.  
    1. Rahimi-Levene N, Koren-Michowitz M, Zeidenstein R, Peer V, Golik A, Ziv-Baran T. Lower hemoglobin transfusion trigger is associated with higher mortality in patients hospitalized with pneumonia. Medicine (Baltimore). 2018;97(12):e0192 10.1097/MD.0000000000010192 - DOI - PMC - PubMed
  33.  
    1. Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(5):1233–4. 10.1111/jth.14820 - DOI - PMC - PubMed
  34.  
    1. Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med. 2020. 10.1056/NEJMc2013656 - DOI - PMC - PubMed
  35.  
    1. Garcia-Olive I, Sintes H, Radua J, Abad Capa J, Rosell A. D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respir Med. 2020;169:106023 10.1016/j.rmed.2020.106023 . - DOI - PMC - PubMed
  36.  
    1. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190–1. 10.1016/j.cca.2020.03.004 - DOI - PMC - PubMed
  37.  
    1. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128–32. 10.1016/j.ijid.2020.03.053 - DOI - PMC - PubMed
  38.  
    1. Soler MJ, Wysocki J, Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transplant. 2013;28(11):2687–97. 10.1093/ndt/gft320 - DOI - PMC - PubMed
  39.  
    1. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020. 10.1016/S2213-2600(20)30229-0 - DOI - PMC - PubMed
  40.  
    1. Awad A, Al-Nafisi H. Public knowledge of cardiovascular disease and its risk factors in Kuwait: a cross-sectional survey. BMC Public Health. 2014;14:1131 10.1186/1471-2458-14-1131 - DOI - PMC - PubMed
  41.  
    1. Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28(2):74–9. 10.1038/jhh.2013.55 . - DOI - PubMed
  42.  
    1. Alshukry A, Ali H, Ali Y, Al-Taweel T, Abu-farha M, AbuBaker J, et al. Clinical characteristics of Coronavirus Disease 2019 (COVID-19) patients in Kuwait. medRxiv. 2020:2020.06.14.20131045. 10.1101/2020.06.14.20131045 - DOI - PMC - PubMed

Page Navigation